- Home
- PCRX vs NKX Comparison
PCRX vs NKX Comparison
Compare PCRX & NKX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- NKX
- Stock Information
- Founded
- PCRX 2006
- NKX 2002
- Country
- PCRX United States
- NKX United States
- Employees
- PCRX N/A
- NKX N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- NKX Finance/Investors Services
- Sector
- PCRX Health Care
- NKX Finance
- Exchange
- PCRX Nasdaq
- NKX Nasdaq
- Market Cap
- PCRX 1.2B
- NKX 549.4M
- IPO Year
- PCRX 2011
- NKX N/A
- Fundamental
- Price
- PCRX $23.22
- NKX $11.78
- Analyst Decision
- PCRX Buy
- NKX
- Analyst Count
- PCRX 8
- NKX 0
- Target Price
- PCRX $28.38
- NKX N/A
- AVG Volume (30 Days)
- PCRX 569.8K
- NKX 109.3K
- Earning Date
- PCRX 07-29-2025
- NKX 01-01-0001
- Dividend Yield
- PCRX N/A
- NKX 4.37%
- EPS Growth
- PCRX N/A
- NKX N/A
- EPS
- PCRX N/A
- NKX N/A
- Revenue
- PCRX $702,772,000.00
- NKX N/A
- Revenue This Year
- PCRX $7.54
- NKX N/A
- Revenue Next Year
- PCRX $10.78
- NKX N/A
- P/E Ratio
- PCRX N/A
- NKX N/A
- Revenue Growth
- PCRX 3.08
- NKX N/A
- 52 Week Low
- PCRX $11.16
- NKX $9.78
- 52 Week High
- PCRX $27.64
- NKX $12.00
- Technical
- Relative Strength Index (RSI)
- PCRX 35.42
- NKX 54.52
- Support Level
- PCRX $22.82
- NKX $11.68
- Resistance Level
- PCRX $24.36
- NKX $11.82
- Average True Range (ATR)
- PCRX 0.69
- NKX 0.09
- MACD
- PCRX -0.12
- NKX 0.05
- Stochastic Oscillator
- PCRX 17.09
- NKX 84.21
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.